Quince Therapeutics (QNCX) Competitors $1.84 +0.07 (+3.95%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends QNCX vs. ATRA, GBIO, CHRS, CGEN, ADVM, JSPR, DSGN, LYEL, SAGE, and KODShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Atara Biotherapeutics (ATRA), Generation Bio (GBIO), Coherus BioSciences (CHRS), Compugen (CGEN), Adverum Biotechnologies (ADVM), Jasper Therapeutics (JSPR), Design Therapeutics (DSGN), Lyell Immunopharma (LYEL), Sage Therapeutics (SAGE), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Atara Biotherapeutics Generation Bio Coherus BioSciences Compugen Adverum Biotechnologies Jasper Therapeutics Design Therapeutics Lyell Immunopharma Sage Therapeutics Kodiak Sciences Quince Therapeutics (NASDAQ:QNCX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation. Does the media favor QNCX or ATRA? In the previous week, Atara Biotherapeutics had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 6 mentions for Atara Biotherapeutics and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.92 beat Atara Biotherapeutics' score of 0.35 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of QNCX or ATRA? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Comparatively, 3.7% of Atara Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, QNCX or ATRA? Quince Therapeutics has higher earnings, but lower revenue than Atara Biotherapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.48Atara Biotherapeutics$8.57M7.18-$276.13M-$25.78-0.41 Is QNCX or ATRA more profitable? Quince Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Atara Biotherapeutics' return on equity of 0.00% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Atara Biotherapeutics -132.58%N/A -90.16% Which has more volatility and risk, QNCX or ATRA? Quince Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Do analysts recommend QNCX or ATRA? Quince Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 361.96%. Atara Biotherapeutics has a consensus price target of $16.67, suggesting a potential upside of 56.05%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Quince Therapeutics is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Atara Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the MarketBeat Community believe in QNCX or ATRA? Atara Biotherapeutics received 428 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 67.39% of users gave Atara Biotherapeutics an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes4100.00% Underperform VotesNo VotesAtara BiotherapeuticsOutperform Votes43267.39% Underperform Votes20932.61% SummaryQuince Therapeutics beats Atara Biotherapeutics on 11 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$80.96M$2.93B$5.05B$8.82BDividend YieldN/A1.89%5.17%4.07%P/E Ratio-1.4845.44125.6917.78Price / SalesN/A359.341,179.7874.25Price / CashN/A160.0933.7732.53Price / Book0.933.734.684.68Net Income-$31.39M-$41.63M$119.54M$226.08M7 Day Performance15.72%-7.95%-2.46%-2.04%1 Month Performance131.45%-7.17%-4.08%0.06%1 Year Performance109.09%23.03%29.82%24.60% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$77.88MN/A-1.4860ATRAAtara Biotherapeutics3.8122 of 5 stars$10.68-2.8%$16.67+56.1%-23.4%$63.30M$8.57M0.00165GBIOGeneration Bio3.359 of 5 stars$1.35-2.9%$7.50+455.6%+7.1%$92.84M$5.90M0.00150CHRSCoherus BioSciences3.8289 of 5 stars$1.10+34.1%$6.13+456.8%-46.9%$94.65M$257.24M0.00246High Trading VolumeCGENCompugen2.7226 of 5 stars$1.43-0.7%$4.00+179.7%+121.5%$128.50M$33.46M71.5068ADVMAdverum Biotechnologies4.1779 of 5 stars$6.17-1.3%$27.83+351.1%-32.5%$130.01M$3.60M0.00190Analyst ForecastShort Interest ↓JSPRJasper Therapeutics2.6633 of 5 stars$20.98+1.4%$74.86+256.8%+227.3%$310.38MN/A0.0020DSGNDesign Therapeutics1.7551 of 5 stars$5.48flat$7.00+27.7%+145.7%$310.28MN/A0.0040LYELLyell Immunopharma0.4947 of 5 stars$1.03-7.2%$1.00-2.9%-46.9%$309.93M$130,000.00-1.30270High Trading VolumeSAGESage Therapeutics4.2697 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M-0.88690Analyst ForecastNews CoverageGap DownKODKodiak Sciences2.983 of 5 stars$5.79+2.7%$3.50-39.6%+138.3%$296.80MN/A0.0090 Related Companies and Tools Related Companies Atara Biotherapeutics Alternatives Generation Bio Alternatives Coherus BioSciences Alternatives Compugen Alternatives Adverum Biotechnologies Alternatives Jasper Therapeutics Alternatives Design Therapeutics Alternatives Lyell Immunopharma Alternatives Sage Therapeutics Alternatives Kodiak Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QNCX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
